BioLife CMO sells 344 shares in tax sale plan
BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioLife Solutions' Chief Marketing Officer reported a small insider sale of company stock. On 01/06/2026, Todd Berard sold 344 shares of BioLife Solutions common stock at a price of $25.59 per share, leaving him with 132,564 shares beneficially owned directly after the transaction.
According to the disclosure, this sale was made under a pre-arranged Rule 10b5-1(c) trading plan adopted effective 01/03/2023 and was executed to satisfy tax withholding obligations related to the vesting of restricted stock. This indicates the transaction was part of tax and compensation administration rather than a discretionary open-market sale.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 344 | $25.59 | $9K |
Footnotes (1)
- F1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BioLife Solutions (BLFS) report in this Form 4?
Was the BioLife Solutions CMO’s stock sale made under a Rule 10b5-1 plan?
What role does the reporting person hold at BioLife Solutions (BLFS)?
Is this BioLife Solutions Form 4 filed for one or multiple reporting persons?
AI-generated analysis. How Rhea-AI works. Not financial advice.